Labidi-Galy SI, de La Motte Rouge T, Derbel O, et al. - Researchers sought for the factors that are linked to prolonged progression-free survival (PFS) and overall survival (OS) in relapsing epithelial ovarian cancer (EOC) patients with BRCA mutations and receiving olaparib as maintenance therapy in daily practice. In this multicenter (8 hospitals) European retrospective study, they included 115 patients (median age: 54 years) who had germline or somatic mutations of BRCA1/BRCA2 genes and were treated with olaparib as maintenance therapy after platinum-based chemotherapy. These patients exhibited median PFS of 12.7 months and median OS of 35.4 months. Among these patients, prolonged PFS, and OS were observed in correlation with platinum-free interval ≥ 12 months, complete response and normalized CA-125 levels after ultimate platinum-based chemotherapy.